Search

everythinglearnresearchcommunity

for

Search:↓

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

A rare autoimmune disease caused the woman's scalp blisters and hair loss, successfully treated with medication.

A new treatment plan helps manage folliculitis decalvans effectively.

Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.

Antituberculosis drugs can cause severe skin reactions, requiring careful diagnosis and treatment.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Interface dermatitis is the most common skin change in drug-induced hypersensitivity syndrome.

Individualized treatments may help manage Dercum's disease symptoms.

Nearly half of children with primary immunodeficiency disorders showed skin problems, often as the first sign of their condition.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

A patient lost all their hair while on rheumatoid arthritis medication.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.

Two cycles of ABVD chemotherapy followed by 20 Gy radiotherapy is the new standard for early-stage Hodgkin lymphoma due to lower toxicity and similar effectiveness.

Baricitinib is a safe and effective treatment for severe alopecia areata.

Topical eflornithine helps maintain hair reduction after IPL therapy in women with facial hirsutism.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

The session covered updates on skin treatments, including radiotherapy, imiquimod, acitretin, JAK inhibitors, and strategies for managing rosacea and preventing surgical infections.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

Pulsed dye laser treatment was effective for a skin condition resistant to other treatments.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Finasteride didn't significantly improve ICPPS symptoms, more research needed.

Ocrelizumab may cause pancreatitis in some patients.

Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.

Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.